Adenosine Deaminase Deficiency

For the why behind the fact

Use this page to connect what you are memorizing.

Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.

Overview


Plain-Language Overview

Adenosine deaminase (ADA) deficiency is an inherited problem in purine breakdown. Substances that should be cleared build up and damage infection-fighting lymphocytes. The severe form, ADA-SCID, causes dangerous infections, persistent diarrhea and poor growth early in infancy. Some people retain enough enzyme function to develop a milder combined immune deficiency later in childhood or adulthood. Early detection and specialist treatment can restore immune function; ADA deficiency can also affect organs outside the immune system.

Clinical Definition

ADA deficiency is an autosomal recessive purine-metabolism disorder caused by biallelic pathogenic variants in ADA (ADA1). Accumulating deoxyadenosine and dATP are toxic to lymphocytes. Classic ADA-SCID produces T−B−NK− lymphopenia and loss of cellular and humoral immunity. Residual enzyme activity can produce delayed/late-onset combined immunodeficiency; benign partial deficiency confined predominantly to erythrocytes also exists. These phenotypes require biochemical and immune correlation. ADA2 deficiency is a different disorder.

Inciting Event

  • There is no external trigger; disease results from inherited deficiency of ADA enzyme.

  • The enzyme defect is present from birth. Symptoms depend on residual activity, immune dysfunction and exposures; waning maternal antibody is not the cause of ADA deficiency.

  • Exposure to common pathogens triggers severe infections due to immunodeficiency.

Latency Period

  • Untreated classic ADA-SCID can cause serious infection in the first weeks to months of life; there is no required symptom-free 3-6-month interval.

  • Some affected newborns appear well, but maternal IgG does not correct cellular immunodeficiency or eliminate early infection risk. Screening can detect disease before symptoms.

  • Residual ADA activity can delay combined immunodeficiency until later childhood or adulthood; immune function may deteriorate over time.

Diagnostic Delay

  • Early symptoms mimic common infections, leading to misdiagnosis as recurrent viral or bacterial infections.

  • SCID newborn screening is available throughout the US, but missed follow-up or normal TRECs in delayed ADA deficiency can still delay diagnosis. Persistent suggestive illness warrants evaluation despite a normal screen.

  • Immunodeficiency may be attributed to other causes without specific ADA enzyme activity testing.

  • Failure to recognize characteristic lymphopenia and opportunistic infections prolongs diagnostic delay.

Clinical Presentation


Signs & Symptoms

  • Recurrent severe infections including bacterial, viral, and fungal pathogens

  • Chronic diarrhea and failure to thrive in infancy

  • Oral candidiasis and other opportunistic infections

  • Pneumocystis jirovecii pneumonia is a common presenting infection

  • Persistent fever or respiratory illness may reflect infection; lymphopenia itself is identified by blood testing, not by a specific symptom.

History of Present Illness

  • Recurrent, severe bacterial, viral, and fungal infections including pneumonia and otitis media.

  • Chronic diarrhea and failure to thrive due to malabsorption and systemic illness.

  • Persistent oral thrush and candidiasis reflecting impaired cellular immunity.

  • Document dermatitis, organ enlargement or autoimmune features when present; these require assessment for infection or immune dysregulation and are not simply symptoms of a low lymphocyte count.

Past Medical History

  • Review newborn screening, prior infections, growth and nonimmune abnormalities; ADA deficiency can be detected before any previous diagnosis.

  • May have history of recurrent infections since early infancy.

  • Review medications, transfusions and prior immune treatments, which can alter testing; an apparently unremarkable history does not exclude ADA deficiency.

Family History

  • Siblings or relatives with early infant deaths from infections suggestive of immunodeficiency.

  • If both parents carry a disease-causing ADA variant, each pregnancy has a 25% risk of an affected child. Consanguinity increases the chance of sharing a recessive variant.

  • Family history of primary immunodeficiency syndromes or known ADA mutations.

Physical Exam Findings

  • Scant tonsillar or lymph-node tissue may support SCID, interpreted for age; lymphopenia is a laboratory finding, not a physical examination sign.

  • Failure to thrive and cachexia in infants due to recurrent infections

  • Chronic diarrhea and oral thrush from opportunistic infections

  • Hepatosplenomegaly, when present, prompts assessment for infection or immune dysregulation; it is not required for ADA-SCID.

  • Dermatitis or erythroderma may occur. In SCID, consider infection, immune dysregulation or maternal T-cell engraftment rather than assuming ordinary eczema.

Diagnostic Workup


Diagnostic Criteria

Suspected SCID requires urgent specialist immunology evaluation and protective care. Establish ADA deficiency with markedly deficient RBC ADA activity in an untransfused patient with compatible findings and/or biallelic pathogenic or likely pathogenic ADA variants; both tests are commonly obtained. Elevated RBC dATP/total deoxyadenosine nucleotides (dAXP) support the metabolic diagnosis. Obtain pretreatment samples when feasible, but do not delay urgent care: transfusions and enzyme replacement alter biochemical interpretation. Assess age-adjusted T/B/NK counts and function, immunoglobulins and infection status. Low TRECs are a screen, not a gene-specific diagnosis, and benign partial ADA deficiency requires clinical/biochemical distinction.

Pathophysiology


Key Mechanisms

  • ADA normally converts adenosine to inosine and deoxyadenosine to deoxyinosine. Deficiency allows substrate accumulation and intracellular buildup of dATP.

  • Excess dATP inhibits ribonucleotide reductase, disrupting DNA synthesis; additional purine-metabolite effects, including impaired methylation reactions, contribute to lymphocyte injury and apoptosis.

  • Classic ADA-SCID causes profound T-, B- and NK-cell depletion, impairing cellular and humoral defenses. Residual enzyme function can produce a less severe combined immune defect.

  • Accumulation of toxic metabolites also causes non-immune systemic toxicity affecting multiple organs.

InvolvementDetails
Organs

Lymph nodes are small and underdeveloped due to lymphocyte depletion.

The spleen and other lymphoid tissues can show lymphocyte depletion; spleen size varies and enlargement can accompany infection or immune dysregulation.

The lungs are vulnerable to opportunistic infection and to noninfectious disease such as alveolar proteinosis.

Tissues

Bone marrow is affected by toxic metabolites impairing hematopoiesis and lymphoid progenitor cell survival.

Thymus tissue is hypoplastic due to impaired T cell maturation and development.

Cells

T lymphocytes are markedly depleted and dysfunctional in classic ADA-SCID because toxic purine metabolites impair their development and survival.

B lymphocytes are typically depleted in classic ADA-SCID, and antibody production is impaired; counts alone do not establish functional immunity.

NK cells are typically low in classic ADA-SCID; the severity of depletion varies with residual enzyme activity and phenotype.

Chemical Mediators

Deoxyadenosine and dATP accumulate due to ADA deficiency, causing lymphotoxicity and apoptosis.

Adenosine deaminase enzyme deficiency leads to toxic purine metabolite buildup disrupting DNA synthesis in lymphocytes.

Treatments


Pharmacological Treatments

  • Enzyme Replacement: Elapegademase-lvlr (PEG-ADA)

    • Mechanism:
      • PEGylated recombinant ADA supplies extracellular enzyme activity, lowering adenosine/deoxyadenosine and toxic nucleotide accumulation. Monitor trough plasma ADA, RBC dAXP and immune recovery.

    • Side effects:
      • Injection-site discomfort/bleeding; IM dosing requires caution with thrombocytopenia and should be avoided when it is severe.

      • Anti-drug/anti-PEG antibodies may reduce enzyme activity; falling activity requires investigation and monitoring.

      • Cough and vomiting were commonly reported in small trials; adverse-event estimates are limited by very small samples.

    • Clinical role:
      • Initial metabolic treatment/bridge to HSCT or gene therapy; may continue when definitive treatment is unavailable. Not curative, and infection precautions remain until immune recovery.

  • Allogeneic Hematopoietic Stem Cell Transplantation (Cellular Therapy)

    • Mechanism:
      • Donor hematopoietic stem cells generate functional immune cells; selection of donor and conditioning is individualized. This is a transplant procedure, not a conventional drug.

    • Side effects:
      • Graft-versus-host disease can occur even with an HLA-matched donor; graft failure is another major risk.

      • Infections during immune reconstitution; continue specialist-directed prophylaxis and monitoring.

      • Conditioning-related organ toxicity and cytopenias depend on the transplant regimen.

    • Clinical role:
      • Potentially curative immune treatment, particularly with a suitable matched related donor; compare donor options and available gene therapy at an expert center. Systemic complications still need follow-up.

  • Autologous Hematopoietic Stem Cell Gene Therapy (Cellular Therapy)

    • Mechanism:
      • A functional ADA gene is added ex vivo to the patient's CD34+ stem cells, which are reinfused after conditioning to generate ADA-expressing blood/immune cells.

    • Side effects:
      • Insertional oncogenesis: T-cell leukemia has occurred after gamma-retroviral ADA gene therapy; long-term surveillance is required. Vector-specific evidence matters.

      • Conditioning can cause infection and organ toxicity; response can be incomplete or fail, requiring additional treatment.

      • Conditioning-related cytopenias; monitor immune recovery and clonal expansion. Autologous cells avoid the allogeneic-donor mechanism of GVHD.

    • Clinical role:
      • Potentially curative alternative to allogeneic HSCT in eligible patients at specialist centers; access and approved indications vary by region/product. It is not universally a second-line drug.

Non-pharmacological Treatments

  • Immediate protective care and specialist referral for suspected SCID; minimize infectious exposure while promptly identifying and treating infections. Starting enzyme replacement does not immediately restore immunity.

  • Allogeneic HSCT or autologous stem-cell gene therapy can provide definitive immune treatment. Selection depends on donor availability, patient status and specialist-center access; enzyme replacement often provides initial stabilization.

  • Provide nutritional support and growth monitoring. For infants with suspected SCID, the specialist team should establish a feeding plan that addresses maternal CMV status and breast-milk transmission risk.

Prevention


Pharmacological Prevention

  • PEG-ADA enzyme replacement, including elapegademase-lvlr, treats the metabolic defect and can reduce infection risk; it does not prevent inheritance or permanently correct the gene defect.

  • Provide Pneumocystis jirovecii prophylaxis and specialist-directed antifungal prophylaxis. Agent selection, timing and monitoring depend on age, blood counts and clinical status.

  • Immunoglobulin replacement provides passive antibody protection while humoral immunity is inadequate; it does not correct the T-cell defect.

  • Use viral surveillance and targeted antiviral prevention/treatment according to exposure and infection status, especially for CMV; one regimen does not suit every patient.

  • HSCT and stem-cell gene therapy are definitive cellular treatments, not pharmacological prevention; ongoing infection prophylaxis is needed until adequate immune reconstitution.

Non-pharmacological Prevention

  • Avoidance of live vaccines due to immunodeficiency

  • Strict infection control measures including hand hygiene and isolation

  • Offer genetic counseling and testing of at-risk relatives. For a newborn with known familial risk, arrange immediate diagnostic assessment rather than relying on routine screening alone.

  • Newborn screening and prompt confirmatory testing allow early treatment. Low TRECs are not ADA-specific, and delayed ADA disease may have normal TRECs; ADA-specific metabolite screening is available in selected programs.

  • Nutritional support and growth monitoring to optimize health

Outcome & Complications


Complications

  • Life-threatening opportunistic infections due to profound immunodeficiency

  • Chronic lung disease from recurrent infections

  • Neurologic, behavioral or hearing abnormalities can accompany systemic ADA deficiency; infection and treatment may also contribute.

  • Failure to thrive and developmental delay

  • GVHD can follow allogeneic HSCT even with a matched donor; in SCID it can also follow engraftment of maternal lymphocytes or non-irradiated donor lymphocytes.

Short-term Sequelae Long-term Sequelae
  • Severe infections requiring hospitalization and intravenous antibiotics

  • Respiratory failure from pneumonia or pneumonitis

  • Sepsis due to overwhelming infection

  • Electrolyte imbalances from diarrhea and malabsorption

  • Acute respiratory distress syndrome (ARDS) in severe pulmonary infections

  • Chronic lung disease with bronchiectasis

  • Neurodevelopmental or hearing problems may persist despite immune reconstitution; long-term systemic follow-up is needed.

  • Growth retardation and failure to thrive

  • Autoimmunity and immune dysregulation can occur, particularly in delayed disease or incomplete immune recovery; they are not excluded by ADA deficiency.

  • Lymphoma risk is associated with persistent immune dysfunction. Gene-therapy recipients also require surveillance for vector-related malignancy; these are distinct mechanisms.

Differential Diagnoses


Adenosine Deaminase Deficiency versus X-linked Severe Combined Immunodeficiency (SCID)

Adenosine Deaminase Deficiency

X-linked Severe Combined Immunodeficiency (SCID)

Autosomal recessive inheritance affecting both sexes equally

X-linked recessive inheritance affecting mostly males

Classic ADA-SCID: T−B−NK−; delayed phenotypes may retain more lymphocytes.

Classic IL2RG SCID: T−B+NK− with impaired B-cell function. Hypomorphic variants can have atypical counts.

Biallelic pathogenic ADA variants and/or deficient ADA activity with elevated toxic deoxyadenosine nucleotides.

A hemizygous pathogenic IL2RG variant disrupts common gamma-chain signaling, including IL-7 for T-cell and IL-15 for NK-cell development.

Adenosine Deaminase Deficiency versus RAG1/RAG2 Deficiency (Including Omenn Syndrome)

Adenosine Deaminase Deficiency

RAG1/RAG2 Deficiency (Including Omenn Syndrome)

Classic T−B−NK− SCID; residual activity produces variable counts and function.

Null RAG deficiency: T−B−NK+. Hypomorphic variants may cause Omenn syndrome with oligoclonal activated T cells, very low B cells and preserved NK cells.

Severe early infections or delayed combined immunodeficiency; autoimmunity and atopy can occur.

Omenn phenotype: erythroderma, lymphadenopathy, hepatosplenomegaly, eosinophilia and elevated IgE. Not every RAG defect causes Omenn syndrome.

Deficient ADA activity/elevated dAXP and/or biallelic pathogenic ADA variants.

Biallelic pathogenic RAG1 or RAG2 variants impair V(D)J recombination, affecting antigen-receptor formation.

Adenosine Deaminase Deficiency versus Purine Nucleoside Phosphorylase (PNP) Deficiency

Adenosine Deaminase Deficiency

Purine Nucleoside Phosphorylase (PNP) Deficiency

Elevated deoxyadenosine/dATP/dAXP; a normal serum urate is not required for diagnosis.

Accumulation of inosine, guanosine and their deoxy forms, often with hypouricemia.

Classic combined T-, B- and NK-cell deficiency, with milder delayed phenotypes.

Predominant T-cell dysfunction; antibody/other lymphocyte findings vary and need measurement.

Biallelic pathogenic ADA variants and/or biochemical ADA deficiency.

Deficient PNP enzyme activity and biallelic pathogenic PNP variants.

Adenosine Deaminase Deficiency versus Chronic Granulomatous Disease (CGD)

Adenosine Deaminase Deficiency

Chronic Granulomatous Disease (CGD)

Classic ADA-SCID causes T−B−NK− lymphopenia, although delayed phenotypes vary.

A phagocyte NADPH oxidase defect; profound combined lymphocyte depletion is not the defining abnormality.

Recurrent infections including opportunistic pathogens like Pneumocystis jirovecii

Recurrent infections with catalase-positive bacteria and fungi (e.g., Staphylococcus aureus, Aspergillus spp.)

Low ADA activity with characteristic purine-metabolite accumulation and/or pathogenic ADA variants.

Reduced DHR oxidative-burst response usually supports CGD; interpret with controls and genetic testing because rare forms and other defects complicate the assay.

Adenosine Deaminase Deficiency versus Common Variable Immunodeficiency (CVID)

Adenosine Deaminase Deficiency

Common Variable Immunodeficiency (CVID)

Usually infancy for ADA-SCID, but delayed ADA-CID can present in childhood or adulthood.

Often recognized later in childhood or adulthood; age distributions overlap.

Classic T−B−NK− SCID or less severe combined immune dysfunction in delayed disease.

Low IgG with low IgA and/or IgM and impaired antibody responses, after excluding other causes. T-cell counts are often preserved, but abnormalities occur.

Early opportunistic infection in classic SCID; later disease may include sinopulmonary infections, autoimmunity or atopy.

Recurrent sinopulmonary infections, sometimes with autoimmunity, granulomatous disease or lymphoproliferation; profound T-cell dysfunction warrants assessment for a combined immune defect.